{"_buckets": {"deposit": "d361a361-a115-473f-a8eb-48a6513f7b70"}, "_deposit": {"id": "3770", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "3770"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00003770"}, "item_6_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2013-06", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "530", "bibliographicPageStart": "524", "bibliographicVolumeNumber": "18", "bibliographic_titles": [{"bibliographic_title": "INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY"}]}]}, "item_6_description_20": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "We compared the efficacy and safety of 1- and 3-month depots of the luteinizing hormone-releasing hormone (LH-RH) agonist goserelin acetate in prostate cancer patients. Patients were randomly assigned to the Direct Group that received the goserelin 3-month depot or the Switch Group that began with the 1-month depot for the first 3 months and then switched to the 3-month depot. All patients were co-administered the antiandrogen agent bicalutamide. Serum testosterone and prostate-specific antigen (PSA) levels and adverse events were recorded at weeks 4, 8, 12, and 24. Baseline testosterone levels in the Direct and Switch Groups were 4.98 and 5.07 ng/mL, respectively (P = 0.798). At each week, the levels in both groups were a parts per thousand currency sign0.50 ng/mL (castration level) with no significant differences between them. All of the patients in the Switch Group and 98.1 % in the Direct Group had achieved castration levels at week 12, and 100 % had achieved such levels at week 24. Baseline PSA levels in the Direct and Switch Groups were 52.37 and 46.72 ng/mL, respectively (P = 0.793). Levels in both groups dropped continuously, to about 1.0 ng/mL at week 24, with no significant differences between the groups at any time. Three patients in the Direct Group experienced adverse events that were attributed to the co-administered bicalutamide. There was no difference in the efficacy or safety between the 1- and 3-month depots of goserelin when given as initial prostate cancer treatment in combination with bicalutamide. Patients must be monitored for adverse events associated with bicalutamide.", "subitem_description_type": "Abstract"}]}, "item_6_description_30": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7\uff08\u30b3\u30f3\u30c6\u30f3\u30c4\u306e\u7a2e\u985e\uff09", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_description_5": {"attribute_name": "\u5f15\u7528", "attribute_value_mlt": [{"subitem_description": "INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY. 18(3):524-530 (2013)", "subitem_description_type": "Other"}]}, "item_6_link_3": {"attribute_name": "\u4fe1\u5dde\u5927\u5b66\u7814\u7a76\u8005\u7dcf\u89a7\u3078\u306e\u30ea\u30f3\u30af", "attribute_value_mlt": [{"subitem_link_text": "Ishizuka, Osamu", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.gmfaHekh.html"}, {"subitem_link_text": "Nishizawa, Osamu", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.WeyeWmyU.html"}]}, "item_6_link_67": {"attribute_name": "WoS", "attribute_value_mlt": [{"subitem_link_text": "Web of Science", "subitem_link_url": "http://gateway.isiknowledge.com/gateway/Gateway.cgi?\u0026GWVersion=2\u0026SrcAuth=ShinshuUniv\u0026SrcApp=ShinshuUniv\u0026DestLinkType=FullRecord\u0026DestApp=WOS\u0026KeyUT=000320456500025"}]}, "item_6_publisher_4": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "SPRINGER JAPAN KK"}]}, "item_6_relation_47": {"attribute_name": "PubMed", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "22552359"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=search\u0026DB=pubmed\u0026term=22552359", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1007/s10147-012-0413-9"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://dx.doi.org/10.1007/s10147-012-0413-9", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_62": {"attribute_name": "\u6a29\u5229", "attribute_value_mlt": [{"subitem_rights": "The original publication is available at www.springerlink.com"}]}, "item_6_select_64": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1341-9625", "subitem_source_identifier_type": "ISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1341-9625", "subitem_source_identifier_type": "ISSN"}]}, "item_6_source_id_40": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AA11086579", "subitem_source_identifier_type": "NCID"}]}, "item_6_text_69": {"attribute_name": "wosonly authkey", "attribute_value_mlt": [{"subitem_text_value": "Prostate cancer; Androgen deprivation therapy; Luteinizing hormone-releasing hormone agonist"}]}, "item_6_text_70": {"attribute_name": "wosonly keywords", "attribute_value_mlt": [{"subitem_text_value": "SERUM TESTOSTERONE; CARCINOMA; CASTRATION; GOSERELIN; ESTROGEN; ACETATE; FAILURE"}]}, "item_6_textarea_68": {"attribute_name": "wosonly abstract", "attribute_value_mlt": [{"subitem_textarea_value": "We compared the efficacy and safety of 1- and 3-month depots of the luteinizing hormone-releasing hormone (LH-RH) agonist goserelin acetate in prostate cancer patients. Patients were randomly assigned to the Direct Group that received the goserelin 3-month depot or the Switch Group that began with the 1-month depot for the first 3 months and then switched to the 3-month depot. All patients were co-administered the antiandrogen agent bicalutamide. Serum testosterone and prostate-specific antigen (PSA) levels and adverse events were recorded at weeks 4, 8, 12, and 24. Baseline testosterone levels in the Direct and Switch Groups were 4.98 and 5.07 ng/mL, respectively (P = 0.798). At each week, the levels in both groups were a parts per thousand currency sign0.50 ng/mL (castration level) with no significant differences between them. All of the patients in the Switch Group and 98.1 % in the Direct Group had achieved castration levels at week 12, and 100 % had achieved such levels at week 24. Baseline PSA levels in the Direct and Switch Groups were 52.37 and 46.72 ng/mL, respectively (P = 0.793). Levels in both groups dropped continuously, to about 1.0 ng/mL at week 24, with no significant differences between the groups at any time. Three patients in the Direct Group experienced adverse events that were attributed to the co-administered bicalutamide. There was no difference in the efficacy or safety between the 1- and 3-month depots of goserelin when given as initial prostate cancer treatment in combination with bicalutamide. Patients must be monitored for adverse events associated with bicalutamide."}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Ishizuka,  Osamu"}], "nameIdentifiers": [{"nameIdentifier": "6933", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishizawa,  Osamu"}], "nameIdentifiers": [{"nameIdentifier": "6934", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishizawa,  Shuji"}], "nameIdentifiers": [{"nameIdentifier": "6935", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Satoh,  Tomoya"}], "nameIdentifiers": [{"nameIdentifier": "6936", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wajiki,  Masahisa"}], "nameIdentifiers": [{"nameIdentifier": "6937", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kiyokawa,  Hideo"}], "nameIdentifiers": [{"nameIdentifier": "6938", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Inoue,  Yoshihiro"}], "nameIdentifiers": [{"nameIdentifier": "6939", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kobayashi,  Shinya"}], "nameIdentifiers": [{"nameIdentifier": "6940", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mizusawa,  Hiroya"}], "nameIdentifiers": [{"nameIdentifier": "6941", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakagawa,  Tatsuo"}], "nameIdentifiers": [{"nameIdentifier": "6942", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-09-24"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Comparison_efficacy_safety_1-and 3-month_luteinizing.pdf", "filesize": [{"value": "192.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 192300.0, "url": {"label": "Comparison_efficacy_safety_1-and 3-month_luteinizing.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/3770/files/Comparison_efficacy_safety_1-and 3-month_luteinizing.pdf"}, "version_id": "58a1d3a0-b419-4806-a873-52b593fe4c00"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "Prostate cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Androgen deprivation therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Luteinizing hormone-releasing hormone agonist", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Comparison of efficacy and safety of 1-and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Comparison of efficacy and safety of 1-and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer"}]}, "item_type_id": "6", "owner": "1", "path": ["461/462"], "permalink_uri": "http://hdl.handle.net/10091/17334", "pubdate": {"attribute_name": "\u516c\u958b\u65e5", "attribute_name_i18n": "\u516c\u958b\u65e5", "attribute_value": "2014-01-21"}, "publish_date": "2014-01-21", "publish_status": "0", "recid": "3770", "relation": {}, "relation_version_is_last": true, "title": ["Comparison of efficacy and safety of 1-and 3-month luteinizing hormone-releasing hormone agonist depots as initial therapies for prostate cancer"], "weko_shared_id": null}